Free tool
FAERS Monitor: Vevye
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217469 or its brand name (Vevye, Cyclosporine). Reports on generic versions are filed under their own applications.
Reports
6,159
Serious
85
1% of reports
Hospitalization
20
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation2,454
- drug ineffective1,688
- eye pain916
- ocular hyperaemia538
- vision blurred479
- eye pruritus407
- dry eye296
- lacrimation increased272
- ocular discomfort243
- headache209
- drug hypersensitivity205
- eye swelling159
- condition aggravated145
- hypersensitivity144
- foreign body sensation in eyes96
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 974 |
| 2025 | 1,814 |
| 2026 | 3,368 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,000 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye irritationSignal | 2,454 | 152.0 | 147.3 | 353,335 |
| ocular discomfortSignal | 243 | 75.5 | 66.7 | 17,419 |
| eye painSignal | 916 | 56.3 | 53.0 | 49,062 |
| foreign body sensation in eyesSignal | 96 | 52.2 | 42.7 | 4,700 |
| eye pruritusSignal | 407 | 41.9 | 38.1 | 16,022 |
| ocular hyperaemiaSignal | 538 | 39.1 | 36.1 | 19,778 |
| lacrimation increasedSignal | 272 | 31.0 | 27.6 | 7,810 |
| dry eyeSignal | 296 | 20.4 | 18.2 | 5,412 |
| eye swellingSignal | 159 | 14.7 | 12.6 | 2,004 |
| vision blurredSignal | 479 | 12.0 | 11.0 | 4,811 |
| drug ineffectiveSignal | 1,688 | 4.4 | 4.2 | 4,685 |
| drug hypersensitivitySignal | 205 | 3.6 | 3.2 | 389 |
| hypersensitivitySignal | 144 | 2.7 | 2.3 | 148 |
| condition aggravated | 145 | 1.6 | 1.4 | 35 |
| headache | 209 | 1.1 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.